| Filed On | Filing |
|---|---|
| 28 Oct 2026 |
8-K: Results of Operations and Financial Condition
Biogen Inc. (Nasdaq: BIIB) today reported third quarter 2026 financial results. |
| 29 Jul 2026 |
8-K: Results of Operations and Financial Condition
Biogen Inc. (Nasdaq: BIIB) today reported second quarter 2026 financial results. |
| 01 Jul 2026 |
8-K: Results of Operations and Financial Condition
Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $164 million on a pre-tax basis. The... |
| 10 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 9, 2026, Biogen Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders. The final voting results for this meeting are as follows: |
| 14 May 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
This TERM LOAN CREDIT AGREEMENT (this “Agreement”) is entered into as of May 12, 2026, among BIOGEN INC., a Delaware corporation (the “Borrower”), each Lender from time to time party hereto, and U.S. BANK NATIONAL ASSOCIATION, as the Adm... |
| 29 Apr 2026 |
8-K: Results of Operations and Financial Condition
First quarter 2026 total revenue of $2.5 billion, increased 2% year-over-year; GAAP diluted EPS of $2.15, increased 31% year-over-year; Non-GAAP diluted EPS of $3.57, increased 18% year-over-year |
| 06 Apr 2026 |
8-K: Results of Operations and Financial Condition
Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the first quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $34 million on a pre-tax basis. The e... |
| 31 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Exhibit A Form of Certificate of Incorporation of the Surviving Corporation |
| 11 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 11 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 06 Feb 2026 |
8-K: Results of Operations and Financial Condition
Full year 2025 total revenue $9.9 billion; GAAP diluted EPS $8.79; Non-GAAP diluted EPS $15.28, exceeding the upper end of our 2025 full year guidance range of $14.50 to $15.00 |
| 14 Jan 2026 |
8-K: Results of Operations and Financial Condition
Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the fourth quarter of 2025 will include acquired in-process research and development, upfront and milestone expense of approximately $222 million on a pre-tax basis. The... |
| 30 Oct 2025 |
8-K: Results of Operations and Financial Condition
Third quarter 2025 total revenue of $2.5 billion, increased 3% year-over-year; GAAP diluted EPS of $3.17, increased 19% year-over-year; Non-GAAP diluted EPS of $4.81, increased 18% year-over-year |
| 14 Oct 2025 |
8-K: Results of Operations and Financial Condition
Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the third quarter of 2025 will include acquired in-process research and development, upfront and milestone expense of approximately $2 million on a pre-tax basis. The es... |
| 31 Jul 2025 |
8-K: Results of Operations and Financial Condition
Second quarter 2025 total revenue $2.6 billion, increased 7% year-over-year; GAAP diluted EPS $4.33, increased 8% year-over-year; Non-GAAP diluted EPS $5.47, increased 4% year-over-year |
| 07 Jul 2025 |
8-K: Results of Operations and Financial Condition
Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2025 will include acquired in-process research and development, upfront and milestone expense of approximately $46 million on a pre-tax basis. The ... |
| 23 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2025, Biogen Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The final voting results for the Annual Meeting are as follows: |
| 12 May 2025 |
8-K: Other Events
SUPPLEMENTAL INDENTURE (this “Fourth Supplemental Indenture”), dated as of May 12, 2025, between BIOGEN INC., a Delaware corporation (the “Company”), and U.S. Bank Trust Company, National Association, a national association (as successor... |
| 01 May 2025 |
8-K: Results of Operations and Financial Condition
First quarter 2025 total revenue $2.4 billion, increased 6% year-over-year; GAAP diluted EPS $1.64; Non-GAAP diluted EPS $3.02 |
| 12 Feb 2025 |
8-K: Results of Operations and Financial Condition
Fourth quarter 2024 total revenue $2.5 billion, 3% growth YoY; GAAP diluted EPS $1.83, 7% growth YoY; Non-GAAP diluted EPS $3.44, 17% growth YoY |
Loading...